University of Massachusetts Chan Medical School

Running trials

• Not yet recruiting

  The Study of Brave-LC LDN Treatment Trial

  NCT07916259· Phase 3· National Institute of Allergy and Infectious Diseases (NIAID)· Source

• Not yet recruiting

  Botulinum Toxin Blockade of Neuronal Signals to Immune Cells as a Novel Treatment for Hidradenitis Suppurativa

  NCT07756346· Phase 2· University of Massachusetts, Worcester· Source

• Not yet recruiting

  Metformin to Attenuate Progressive Respiratory Decline in Idiopathic Pulmonary Fibrosis

  NCT07520110· Phase 3· University of Massachusetts, Worcester· Source

• Recruiting

  A Phase 3 Study of INCA033989 Versus Best Available Therapy in Participants With Essential Thrombocythemia

  NCT07623200· Phase 3· Incyte Corporation· Source

• Recruiting

  The Medically Tailored Groceries and Mental Health Study

  NCT07779707· University of Massachusetts, Worcester· Source

• Recruiting

  A Study to Learn About the Safety, Tolerability, and Immunogenicity of a Fifth Dose of 6-Valent OspA-Based Lyme Disease Vaccine

  NCT07500506· Phase 3· Pfizer· Source

• Enrolling by invitation

  Facilitation of Information eXchange for Shared Decision Making for Lung Cancer Screening

  NCT07517692· University of Massachusetts, Worcester· Source

• Recruiting

  A Study of Brenipatide in Adult Participants With Schizophrenia

  NCT07410507· Phase 2· Eli Lilly and Company· Source

• Recruiting

  A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

  NCT07174336· Phase 3· Eli Lilly and Company· Source

• Recruiting

  A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract

  NCT07218380· Phase 3· Eli Lilly and Company· Source

• Active, not recruiting

  A Study to Assess Bioequivalence of Two Subcutaneous (SC) Formulations of Ocrelizumab in Participants With Multiple Sclerosis (MS)

  NCT07074886· Phase 2· Hoffmann-La Roche· Source

• Recruiting

  A Study Evaluating the Real-World Experience of Givinostat in Patients With Duchenne Muscular Dystrophy

  NCT07127978· ITF Therapeutics LLC· Source

• Recruiting

  A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer

  NCT07213804· Phase 3· Eli Lilly and Company· Source

• Recruiting

  Evaluation of the Paramedic Evaluation for Acute COPD Exacerbation

  NCT07072039· University of Massachusetts, Worcester· Source

• Recruiting

  Self-administered ONe-of-a Kind Approach to Epilepsy Therapy Through a Web-based Music Application

  NCT06425029· Dartmouth-Hitchcock Medical Center· Source

• Not yet recruiting

  Efficacy and Safety of MSC-NTF (NurOwn) in Participants With Early Symptomatic ALS and Moderate Disease Presentation in ALS (ENDURANCE STUDY)

  NCT06973629· Phase 3· Brainstorm-Cell Therapeutics· Source

• Recruiting

  PRospective phenotypIng and Multi-omic Endotyping of Progressive Pulmonary Fibrosis

  NCT06855329· University of Massachusetts, Worcester· Source

• Recruiting

  RESET-MG: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Generalized Myasthenia Gravis

  NCT06359041· Phase 1/2· Cabaletta Bio· Source

• Active, not recruiting

  A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than Anti-PD1 Alone in Adult Participants With Resectable Stage 3 or 4 Melanoma

  NCT06190951· Phase 2· Regeneron Pharmaceuticals· Source

• Active, not recruiting

  A Study of Obexelimab in Patients With Systemic Lupus Erythematosus

  NCT06559163· Phase 2· Zenas BioPharma (USA), LLC· Source

• Active, not recruiting

  A Study of Obexelimab in Patients With Relapsing Multiple Sclerosis (MoonStone)

  NCT06564311· Phase 2· Zenas BioPharma (USA), LLC· Source

• Enrolling by invitation

  Storytelling for Reducing Gap in Anticoagulation Use in African Americans With Atrial Fibrillation

  NCT05997914· University of Massachusetts, Worcester· Source

• Recruiting

  Asthma Link Effectiveness Trial

  NCT06388460· University of Massachusetts, Worcester· Source

• Recruiting

  Metabolic Effects of Adjunctive Lumateperone Treatment in Clozapine-Treated Patients With Schizophrenia

  NCT06174116· Phase 4· University of Massachusetts, Worcester· Source

• Active, not recruiting

  A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30)

  NCT06215118· Phase 1· Pfizer· Source

• Active, not recruiting

  Ph2 Open-label Study of AOC 1044 in Duchenne Muscular Dystrophy Participants With Mutations Amenable to Exon44 Skipping

  NCT06244082· Phase 2· Avidity Biosciences, Inc.· Source

• Active, not recruiting

  A Study of CC-97540, CD-19-Targeted Nex-T CAR T Cells, in Participants With Severe, Refractory Autoimmune Diseases (Breakfree-1)

  NCT05869955· Phase 1· Juno Therapeutics, Inc., a Bristol-Myers Squibb Company· Source

• Active, not recruiting

  A Study to Evaluate Long-term Safety of Ecopipam Tablets in Children, Adolescents and Adults With Tourette's Disorder

  NCT06021522· Phase 3· Emalex Biosciences Inc.· Source

• Recruiting

  A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML

  NCT05735184· Phase 1· Kura Oncology, Inc.· Source

• Active, not recruiting

  Guselkumab vs Golimumab in PsA TNF Inadequate Responder Patients

  NCT05669833· Phase 3· University of Pennsylvania· Source

• Recruiting

  The Rhythm Evaluation for AntiCoagulaTion With Continuous Monitoring of Atrial Fibrillation

  NCT05836987· Phase 3· Johns Hopkins University· Source

• Enrolling by invitation

  An Open-label Study of XEN1101 in Epilepsy

  NCT05718817· Phase 3· Xenon Pharmaceuticals Inc.· Source

• Enrolling by invitation

  Tobacco Cessation Texting Intervention for People Living With HIV Who Smoke in Vietnam

  NCT05863923· University of Massachusetts, Worcester· Source

• Active, not recruiting

  Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD

  NCT05711940· Phase 3· COMPASS Pathways· Source

• Active, not recruiting

  AFFINITY DUCHENNE: RGX-202 Gene Therapy in Participants With Duchenne Muscular Dystrophy (DMD)

  NCT05693142· Phase 2/3· REGENXBIO Inc.· Source

• Enrolling by invitation

  Supporting Use of AC Through Provider Profiling of Oral AC Therapy for AF IV

  NCT05236556· University of Massachusetts, Worcester· Source

• Active, not recruiting

  A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment

  NCT05455320· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  PREvention of CardIovascular and DiabEtic kidNey Disease in Type 2 Diabetes

  NCT05390892· Phase 4· Brigham and Women's Hospital· Source

• Active, not recruiting

  A Culturally Tailored Dietary Intervention to Treat Crohn's Disease

  NCT05627128· University of Massachusetts, Worcester· Source

• Active, not recruiting

  A Phase 3 Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirrhosis (MAESTRO-NASH-OUTCOMES)

  NCT05500222· Phase 3· Madrigal Pharmaceuticals, Inc.· Source

• Active, not recruiting

  A Research Study to Compare Somapacitan Once a Week With Norditropin® Once a Day in Children Who Need Help to Grow

  NCT05330325· Phase 3· Novo Nordisk A/S· Source

• Enrolling by invitation

  A Study to Learn More About the Long-Term Safety of Litifilimab (BIIB059) Injections and it's Effects on Symptoms in Adults With Systemic Lupus Erythematosus (SLE)

  NCT05352919· Phase 3· Biogen· Source

• Recruiting

  Targeting Nociceptors in Hidradenitis Suppurativa

  NCT05403710· University of Massachusetts, Worcester· Source

• Recruiting

  A Study Investigating Oral Ozanimod (RPC1063) in Pediatric Participants With Moderate to Severe Active Ulcerative Colitis

  NCT05076175· Phase 2/3· Bristol-Myers Squibb· Source

• Recruiting

  A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2

  NCT04879329· Phase 2· Seagen, a wholly owned subsidiary of Pfizer· Source

• Active, not recruiting

  A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)

  NCT05288166· Phase 3· Eli Lilly and Company· Source

• Active, not recruiting

  Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15)

  NCT05173987· Phase 3· Merck Sharp & Dohme LLC· Source

• Recruiting

  A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)

  NCT05139017· Phase 2/3· Merck Sharp & Dohme LLC· Source

• Active, not recruiting

  Pembrolizumab/Placebo Plus Paclitaxel With or Without Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer (MK-3475-B96/KEYNOTE-B96/ENGOT-ov65).

  NCT05116189· Phase 3· Merck Sharp & Dohme LLC· Source

• Recruiting

  Treatment of Acute Ischemic Stroke (ReMEDy2 Trial)

  NCT05065216· Phase 2/3· DiaMedica Therapeutics Inc· Source

Showing 50 of 65.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Atrial fibrillation2 recruiting
• Bladder cancer2 recruiting
• Chronic kidney disease2 recruiting
• Epilepsy2 recruiting
• Hidradenitis suppurativa2 recruiting
• Idiopathic pulmonary fibrosis2 recruiting
• Schizophrenia2 recruiting
• Stroke2 recruiting
• Acute myeloid leukaemia1 recruiting
• ALS (motor neurone disease)1 recruiting
• Asthma1 recruiting
• COPD1 recruiting
• Depression1 recruiting
• Duchenne muscular dystrophy1 recruiting
• HIV1 recruiting
• Long COVID and ME/CFS1 recruiting
• Lung cancer1 recruiting
• Lupus (SLE)1 recruiting
• Lyme disease1 recruiting
• Metastatic breast cancer1 recruiting
• Myasthenia gravis1 recruiting
• Myeloproliferative neoplasms1 recruiting
• Ovarian cancer1 recruiting
• Rheumatoid arthritis1 recruiting
• Sarcoma1 recruiting
• Type 2 diabetes1 recruiting
• Ulcerative colitis1 recruiting

Closed trials

• Recruiting

  A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia

  NCT06948318· Phase 3· Takeda· Source

• Completed

  Data Collection for Echocardiography-Based Software Assessment

  NCT07126600· Anumana, Inc.· Source

• Withdrawn

  Evaluating the Efficacy and Safety of Metformin in Vitiligo

  NCT05607316· Phase 2· University of Massachusetts, Worcester· Source

• Completed

  FIT-COACH: Fitbit Intervention With Coordinated Health Coaching and PCP Support

  NCT06915090· University of Massachusetts, Worcester· Source

• Recruiting

  A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia

  NCT06722235· Phase 3· Takeda· Source

• Completed

  DM-BOOST Para Latinx: a Diabetes Mellitus Program Using Behavioral Economics to Optimize Outreach and Self-management Support With Technology for Latinx Patients

  NCT05583877· Daniel Amante· Source

• Completed

  A Prospective Cohort Study to Assess Clinical Effectiveness of an Investigational Digital Therapeutic (CT-155) in Patients With Experiential Negative Symptoms of Schizophrenia

  NCT06791122· Boehringer Ingelheim· Source

• Completed

  A Study to Explore the Efficacy of JNJ-89495120 in the Treatment of Major Depressive Disorder

  NCT06785012· Phase 2· Janssen Research & Development, LLC· Source

• Completed

  A Program to Reduce Inappropriate Medications Among Older Adults With Alzheimer's Disease: Implementation Phase 2

  NCT06368115· University of Massachusetts, Worcester· Source

• Recruiting

  Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)

  NCT06170788· Phase 3· Merck Sharp & Dohme LLC· Source

• Completed

  Dynamic Quantification of Social-Visual Engagement in Autism Spectrum Disorder (ASD)

  NCT05806216· EarliTec Diagnostics, Inc· Source

• Withdrawn

  Cytomegalovirus (CMV) Transmission and Immune Tracking (TransmIT) Study

  NCT06522880· University of Massachusetts, Worcester· Source

• Completed

  Tele-Navigation of Lung Cancer Screening (Tele-Navi LCS)

  NCT05021133· University of Massachusetts, Worcester· Source

• Recruiting

  Comparison of the Outcomes of Single vs Multiple Arterial Grafts in Women

  NCT04124120· Weill Medical College of Cornell University· Source

• Terminated

  Study to Assess Efficacy and Safety of NS-018 Compared to BAT in Patients With Myelofibrosis

  NCT04854096· Phase 2· NS Pharma, Inc.· Source

• Completed

  Ecopipam Tablets to Study Tourette's Disorder in Children, Adolescents and Adults

  NCT05615220· Phase 3· Emalex Biosciences Inc.· Source

• Completed

  Efficacy, Safety, and Tolerability of COMP360 in Participants With TRD

  NCT05624268· Phase 3· COMPASS Pathways· Source

• Recruiting

  PROMISE III: Percutaneous Deep Vein Arterialization for the Treatment of Late-Stage Chronic Limb-Threatening Ischemia

  NCT05313165· LimFlow, Inc.· Source

• Completed

  Study of AOC 1044 in Healthy Adult Volunteers and Participants With Duchenne Muscular Dystrophy (DMD) Mutations Amenable to Exon 44 Skipping

  NCT05670730· Phase 1/2· Avidity Biosciences, Inc.· Source

• Completed

  Healthy At Home Pilot

  NCT06000696· University of Massachusetts, Worcester· Source

• Recruiting

  A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma

  NCT05548296· Phase 2· Acrivon Therapeutics· Source

• Completed

  An Efficacy, Safety, Tolerability, Immunogenicity, and Lot-Consistency Clinical Trial of a 6-Valent OspA-Based Lyme Disease Vaccine (VLA15)

  NCT05477524· Phase 3· Pfizer· Source

• Completed

  A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream With Phototherapy in Participants With Vitiligo

  NCT05247489· Phase 2· Incyte Corporation· Source

• Completed

  Study of Pembrolizumab/Vibostolimab (MK-7684A) in Combination With Concurrent Chemoradiotherapy Followed by Pembrolizumab/Vibostolimab Versus Concurrent Chemoradiotherapy Followed by Durvalumab in Participants With Stage III Non-small Cell Lung Cancer (MK-7684A-006)

  NCT05298423· Phase 3· Merck Sharp & Dohme LLC· Source

• Completed

  Biomarker-Driven Pharmacological Treatment of Adolescents With Autism Spectrum Disorder With Gabapentin

  NCT05063656· Phase 4· David Cochran· Source

• Completed

  Study to Assess the Effect of Ofatumumab in Treatment Naïve, Very Early RRMS Patients Benchmarked Against Healthy Controls.

  NCT05084638· Phase 4· Novartis Pharmaceuticals· Source

• Terminated

  A Study of HMPL-306 in Advanced Hematological Malignancies With mIDH

  NCT04764474· Phase 1· Hutchmed· Source

• Completed

  Study of Relugolix in Men With Metastatic Castration-Sensitive Prostate Cancer or Non-Metastatic or Metastatic Castration-Resistant Prostate Cancer

  NCT04666129· Phase 1· Sumitomo Pharma America, Inc.· Source

• Completed

  Development and Feasibility Testing of DM-BOOST Intervention.

  NCT04710940· Daniel Amante· Source

• Completed

  Evaluation of AMG 714 for Vitiligo

  NCT04338581· Phase 2· National Institute of Allergy and Infectious Diseases (NIAID)· Source

• Completed

  Pivotal, Randomized, Open-label Study of Optune® (Tumor Treating Fields) Concomitant With RT & TMZ for the Treatment of Newly Diagnosed GBM

  NCT04471844· NovoCure Ltd.· Source

• Completed

  A Study of Esketamine Nasal Spray, Administered as Monotherapy, in Adult Participants With Treatment-resistant Depression

  NCT04599855· Phase 4· Janssen Research & Development, LLC· Source

• Completed

  Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) vs. Standard Chemotherapy and Lenvatinib Monotherapy in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed After Platinum Therapy and Immunotherapy (MK-7902-009/E7080-G000-228/LEAP-009)

  NCT04428151· Phase 2· Merck Sharp & Dohme LLC· Source

• Completed

  A Study of Oral Venetoclax Tablets and Oral Azacitidine as Maintenance Therapy in Adult Participants With Acute Myeloid Leukemia in First Remission After Conventional Chemotherapy

  NCT04102020· Phase 3· AbbVie· Source

• Completed

  Rehabilitation at Home Using Mobile Health In Older Adults After Hospitalization for Ischemic Heart Disease

  NCT03978130· NYU Langone Health· Source

• Completed

  A Study To Investigate The Pharmacokinetics, Safety, And Tolerability Of Subcutaneous Ocrelizumab Administration In Participants With Multiple Sclerosis

  NCT03972306· Phase 1· Hoffmann-La Roche· Source

• Completed

  Efficacy and Safety of Pembrolizumab (MK-3475) With Lenvatinib (E7080/MK-7902) vs. Docetaxel in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) and Progressive Disease (PD) After Platinum Doublet Chemotherapy and Immunotherapy (MK-7902-008/E7080-G000-316/LEAP-008)

  NCT03976375· Phase 3· Merck Sharp & Dohme LLC· Source

• Completed

  Controlled Trial of Brexpiprazole For The Treatment of Co-occurring Schizophrenia and Substance Use Disorder

  NCT03526354· Phase 4· University of Massachusetts, Worcester· Source

• Completed

  Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial

  NCT03500328· Johns Hopkins University· Source

• Completed

  Zenith® p-Branch® Endovascular Graft Pivotal Study

  NCT02396199· Cook Research Incorporated· Source

• Completed

  A Phase 3 Randomized, Placebo-controlled Trial of Carboplatin and Paclitaxel With or Without Veliparib (ABT-888) in HER2-negative Metastatic or Locally Advanced Unresectable BRCA-associated Breast Cancer

  NCT02163694· Phase 3· AbbVie· Source

• Completed

  Framing Eighteen Coils in Cerebral Aneurysms Trial

  NCT01655784· Vanderbilt University Medical Center· Source

• Withdrawn

  Genetic Study of Familial and Sporadic ALS/Motor Neuron Disease, Miyoshi Myopathy and Other Neuromuscular Disorders

  NCT01459302· University of Massachusetts, Worcester· Source

• Completed

  Biomarkers in Tumor Tissue Samples From Patients With Newly Diagnosed Neuroblastoma or Ganglioneuroblastoma

  NCT00904241· Children's Oncology Group· Source

Conditions

Diseases this institution publishes on or runs trials for.

• Atrial fibrillation48 works · 4 trials
• Tuberculosis44 works · 0 trials
• Osteoarthritis37 works · 0 trials
• COPD35 works · 2 trials
• Idiopathic pulmonary fibrosis26 works · 2 trials
• ALS (motor neurone disease)24 works · 3 trials
• Vitiligo18 works · 4 trials
• Lupus (SLE)17 works · 3 trials
• Brain aneurysm15 works · 1 trial
• Aortic aneurysm13 works · 1 trial
• Hepatitis C10 works · 0 trials
• Alopecia areata10 works · 1 trial
• Huntington's disease10 works · 0 trials
• Duchenne muscular dystrophy8 works · 4 trials
• Polycystic ovary syndrome8 works · 0 trials
• Frontotemporal dementia7 works · 1 trial
• Dilated cardiomyopathy6 works · 0 trials
• Spinal muscular atrophy5 works · 0 trials
• Dermatomyositis and polymyositis (myositis)4 works · 1 trial
• Polycystic kidney disease3 works · 0 trials